Circumvent is a biotech company
Circumvent Pharmaceuticals is seeking to address the significant unmet need of neurodegenerative disease patients. Circumvent is targeting heritable forms of neurodegeneration to enable drug discovery and development in both rare and common forms of neurodegenerative disease. Circumvent is funded by NIH/NINDS, YC Bio, Heritage Provider Network, the Longevity Fund, and additional investors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 1, 2021 | Grant | $303K | — | — | — | Detail |
Nov 1, 2021 | Grant | $495K | — | — | — | Detail |
Nov 1, 2021 | Grant | $2.89M | — | — | — | Detail |
Dec 9, 2020 | Seed | $4.09M | 3 | — | — | Detail |
Mar 18, 2019 | Pre-seed | $150K | 1 | Y Combinator | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Y Combinator | Yes | Pre-seed |
DAYLI Financial Group | — | Seed |
Heritage Provider Network | — | Seed |
The Longevity Fund | — | Seed |